Monte Rosa Therapeutics (GLUE) Change in Receivables (2022 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly Change in Receivables of $9000.0 in Q1 2026, up 102.47% quarter-over-quarter from -$365000.0 in Q4 2025, and down 99.27% on a YoY basis from $1.2 million in Q1 2025.
Monte Rosa Therapeutics (GLUE) Change in Receivables (2022 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Change in Receivables history runs 5 years deep, the most recent figure standing at $9000.0 for Q1 2026.
- In Q1 2026, Change in Receivables fell 99.27% year-over-year to $9000.0; the TTM figure through Mar 2026 stood at $3.2 million (up 258.45% YoY), while the FY2025 annual figure was $4.4 million, up 1433.43% from the prior year.
- Change in Receivables was $9000.0 for Q1 2026 at Monte Rosa Therapeutics, up from -$365000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $2.6 million in Q3 2025 to a low of -$2.1 million in Q1 2023.
- Historically, Change in Receivables has averaged $159600.0 across 5 years, with a median of $10000.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables slumped 311.86% in 2023, then soared 12250.0% in 2025.
- A 5-year view of Change in Receivables shows it stood at $10000.0 in 2022, then soared by 3260.0% to $336000.0 in 2023, then plunged by 225.6% to -$422000.0 in 2024, then advanced by 13.51% to -$365000.0 in 2025, then soared by 102.47% to $9000.0 in 2026.
- The last three Change in Receivables figures came in at $9000.0 (Q1 2026), -$365000.0 (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,000.00 |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | -365,000.00 |
| Dec 31, 2025 | -365,000.00 |
| Sep 30, 2025 | 2.60 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 961,000.00 |
| Jun 30, 2025 | 961,000.00 |
| Mar 31, 2025 | 1.24 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | -422,000.00 |
| Dec 31, 2024 | -422,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Jun 30, 2024 | 327,000.00 |
| Jun 30, 2024 | 327,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 336,000.00 |
| Dec 31, 2023 | 336,000.00 |